Quotient Limited (NASDAQ:QTNT) – Jefferies Group lifted their Q3 2018 earnings per share (EPS) estimates for shares of Quotient Limited in a research note issued to investors on Wednesday, according to Zacks Investment Research. Jefferies Group analyst B. Couillard now forecasts that the company will post earnings per share of ($0.55) for the quarter, up from their previous forecast of ($0.63). Jefferies Group currently has a “Buy” rating and a $13.00 target price on the stock. Jefferies Group also issued estimates for Quotient Limited’s Q4 2018 earnings at ($0.46) EPS, FY2018 earnings at ($2.12) EPS, Q1 2019 earnings at ($0.40) EPS, Q2 2019 earnings at ($0.14) EPS, Q3 2019 earnings at ($0.31) EPS, Q4 2019 earnings at ($0.29) EPS, FY2019 earnings at ($1.12) EPS and FY2020 earnings at ($0.23) EPS.
QTNT has been the subject of several other research reports. BTIG Research reissued a “buy” rating and issued a $12.00 price target on shares of Quotient Limited in a report on Wednesday, November 1st. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, ValuEngine cut shares of Quotient Limited from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
COPYRIGHT VIOLATION WARNING: This news story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2017/11/16/quotient-limited-qtnt-to-post-q3-2018-earnings-of-0-55-per-share-jefferies-group-forecasts.html.
Shares of Quotient Limited (QTNT) traded down $0.02 during mid-day trading on Monday, hitting $4.32. 150,400 shares of the stock traded hands, compared to its average volume of 176,357. Quotient Limited has a one year low of $3.22 and a one year high of $7.74. The company has a debt-to-equity ratio of -5.17, a current ratio of 1.36 and a quick ratio of 0.86.
Several hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC raised its holdings in shares of Quotient Limited by 0.3% in the 3rd quarter. Perceptive Advisors LLC now owns 3,726,986 shares of the company’s stock valued at $18,374,000 after purchasing an additional 12,500 shares during the period. New York State Common Retirement Fund bought a new stake in shares of Quotient Limited in the 2nd quarter valued at about $101,000. Goldman Sachs Group Inc. bought a new stake in shares of Quotient Limited in the 2nd quarter valued at about $104,000. Nationwide Fund Advisors acquired a new position in Quotient Limited in the 2nd quarter valued at about $111,000. Finally, Birchview Capital LP grew its stake in Quotient Limited by 36.9% in the 2nd quarter. Birchview Capital LP now owns 79,700 shares of the company’s stock valued at $587,000 after buying an additional 21,500 shares during the last quarter. 47.85% of the stock is currently owned by institutional investors.
In other Quotient Limited news, insider D J. Paul E. Cowan sold 100,000 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $4.41, for a total transaction of $441,000.00. Following the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $117,597.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider D J. Paul E. Cowan sold 45,540 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $3.52, for a total transaction of $160,300.80. Following the sale, the insider now directly owns 26,666 shares in the company, valued at $93,864.32. The disclosure for this sale can be found here. Insiders have sold a total of 320,737 shares of company stock worth $1,418,620 over the last three months. Insiders own 29.00% of the company’s stock.
About Quotient Limited
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.